Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer

Background Lymph node (LN) metastasis is an important predictor of survival for patients with non-small cell lung cancer (NSCLC). However, the prognostic significance of the extent of LN involvement among patients with N1 disease remains unknown. A study was undertaken to evaluate whether involvement of a higher number of N1 LNs is associated with worse survival independent of known prognostic factors. Methods Using the Surveillance, Epidemiology and End Results-Medicare database, 1682 resected patients with N1 NSCLC diagnosed between 1992 and 2005 were identified. As the number of positive LNs is confounded by the total number of LNs sampled, the cases were classified into three groups according to the ratio of positive to total number of LNs removed (LN ratio (LNR)): ≤0.15, 0.16–0.5 and >0.5. Lung cancer-specific and overall survival was compared between these groups using Kaplan–Meier curves. Stratified and Cox regression analyses were used to evaluate the relationship between the LNR and survival after adjusting for potential confounders. Results Lung cancer-specific and overall survival was lower among patients with a high LNR (p<0.0001 for both comparisons). Median lung cancer-specific survival was 47 months, 37 months and 21 months for patients in the ≤0.15, 0.16–0.5 and >0.5 LNR groups, respectively. In stratified and adjusted analyses, a higher LNR was also associated with worse lung cancer-specific and overall survival. Conclusions The extent of LN involvement provides independent prognostic information in patients with N1 NSCLC. This information may be used to identify patients at high risk of recurrence who may benefit from aggressive postoperative therapy.

[1]  E. Halm,et al.  Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. , 2010, American journal of respiratory and critical care medicine.

[2]  Bengt Bergman,et al.  Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Marchetti,et al.  A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. , 2009, Lung cancer.

[4]  J. Flickinger,et al.  Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer , 2009, Cancer.

[5]  P. Goldstraw Staging manual in thoracic oncology , 2009 .

[6]  Alexander Rokitansky,et al.  Thorax , 2009, Pediatric Surgery Digest.

[7]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[8]  C. Divino,et al.  Prognostic significance of the number of lymph node metastases in esophageal cancer. , 2008, Journal of the American College of Surgeons.

[9]  I. Park,et al.  Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. , 2008, The Annals of thoracic surgery.

[10]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Klabunde,et al.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. , 2007, Annals of epidemiology.

[12]  E. Halm,et al.  Sex differences in lung cancer survival: do tumors behave differently in elderly women? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[14]  M. Roh,et al.  Prognostic Significance of Metastatic Lymph Node Ratio in Node-Positive Colon Carcinoma , 2007, Annals of Surgical Oncology.

[15]  P. Pairolero,et al.  Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. , 2006, The Journal of thoracic and cardiovascular surgery.

[16]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[17]  P. Catalano,et al.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Johnstone,et al.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. , 2005, Chest.

[19]  G. Vlastos,et al.  Ratios of involved nodes in early breast cancer , 2004, Breast Cancer Research.

[20]  W. E. Morgan,et al.  Histological determinants of survival in completely resected T1-2N1M0 nonsmall cell cancer of the lung. , 2004, The Annals of thoracic surgery.

[21]  O. Solak,et al.  Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  K. Yasumoto,et al.  Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. , 2004, Lung cancer.

[23]  H. Herr Superiority of ratio based lymph node staging for bladder cancer. , 2003, The Journal of urology.

[24]  A. Marra,et al.  Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. , 2003, The Journal of thoracic and cardiovascular surgery.

[25]  L. Voltolini,et al.  Pneumonectomy vs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? , 2003, The Journal of cardiovascular surgery.

[26]  C. Belluco,et al.  Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience , 2003, Annals of Surgical Oncology.

[27]  Gregory S. Cooper,et al.  Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.

[28]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[29]  H. Wada,et al.  Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[30]  A B de la Rivière,et al.  Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. , 2000, Chest.

[31]  S. Burdett,et al.  Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials , 1998, The Lancet.

[32]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[33]  R. Snijder,et al.  Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. , 1997, The Annals of thoracic surgery.

[34]  Bonny R. Hart,et al.  Prognostic significance of N1 disease in carcinoma of the lung. , 1983, The Journal of thoracic and cardiovascular surgery.

[35]  C. Percy,et al.  Accuracy of cancer death certificates and its effect on cancer mortality statistics. , 1981, American journal of public health.